期刊
NEOPLASIA
卷 13, 期 11, 页码 1019-U45出版社
ELSEVIER SCIENCE INC
DOI: 10.1593/neo.111252
关键词
-
类别
资金
- National Institutes of Health (NIH) [P50 CA69568]
- Early Detection Research Network [U01 CA111275]
- Howard Hughes Medical Institute
- Prostate Cancer Foundation
- Taubman Research Institute
- Doris Duke Foundation
- American Cancer Society [NIH 1 PO1 CA093900, 1 U01CA143055]
The research community at large is expending considerable resources to sequence the coding region of the genomes of tumors and other human diseases using targeted exome capture (i.e., whole exome sequencing). The primary goal of targeted exome sequencing is to identify nonsynonymous mutations that potentially have functional consequences. Here, we demonstrate that whole-exome sequencing data can also be analyzed for comprehensively monitoring somatic copy number alterations (CNAs) by benchmarking the technique against conventional array CGH. A series of 17 matched tumor and normal tissues from patients with metastatic castrate-resistant prostate cancer was used for this assessment. We show that targeted exome sequencing reliably identifies CNAs that are common in advanced prostate cancer, such as androgen receptor (AR) gain and PTEN loss. Taken together, these data suggest that targeted exome sequencing data can be effectively leveraged for the detection of somatic CNAs in cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据